دورية أكاديمية
ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
العنوان: | ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression |
---|---|
المؤلفون: | S. Ludovic, M.A. Codet, M. Rotharmel, P. De Maricourt, J. Boursicot, E. Gaudre Wattinne |
المصدر: | European Psychiatry, Vol 65, Pp S270-S271 (2022) |
بيانات النشر: | Cambridge University Press, 2022. |
سنة النشر: | 2022 |
المجموعة: | LCC:Psychiatry |
مصطلحات موضوعية: | esketamine, Treatment Resistant Depression, retrospective study, Real World Evidence, Psychiatry, RC435-571 |
الوصف: | Introduction Esketamine nasal spray has been developed to treat adults with treatment resistant depression. On Dec.2019, EMA granted a market access approval in this indication. Objectives ESKALE is a descriptive study of treatment resistant depression patients treated with esketamine in France. Methods Observational retrospective study. 157 patients are included in 3 cohorts depending on their treatment initiation date. This abstract presents the second interim results of patients treated with esketamine and whom data collection ranges from Oct.2019 and Sept.2021. Results 66.7% of patients were females. Average age was 49 years old with 26 patients > 65 years old. Duration of the current depressive episode was 26.0 months (mean). 48.8% of patient have > 1 suicide attempt during whole life. At esketamine initiation, 78.2% patients were clinically perceived to have severe depression with a MADRS score of 32.4 (median) and a PHQ9 score of 19.5 (median). For the overall sample, esketamine was prescribed in median as a 3rd line and for 40.5% of patients after neurostimulation. The majority of the patient started esketamine at 28 mg or 56 mg and increased the dose to 84 mg. After 4 months of treatment, clinical benefits are the following: decrease of MADRS total score -16.5 points (median) corresponding to 58% of responders and a PHQ9 total score decrease of -8.6 points (median). No new safety signal detected. Conclusions This second interim analysis describes patients’ profiles and clinical evolution over a longer period and a broader population than the first interim analysis. The conditions of use are consistent with the ones approved by health authorities. Disclosure I (Marie-Alix Codet) works as a full employee at Janssen Cilag |
نوع الوثيقة: | article |
وصف الملف: | electronic resource |
اللغة: | English |
تدمد: | 0924-9338 1778-3585 |
Relation: | https://www.cambridge.org/core/product/identifier/S0924933822006939/type/journal_article; https://doaj.org/toc/0924-9338; https://doaj.org/toc/1778-3585 |
DOI: | 10.1192/j.eurpsy.2022.693 |
URL الوصول: | https://doaj.org/article/291ca810de574584b12e103fe6e11184 |
رقم الأكسشن: | edsdoj.291ca810de574584b12e103fe6e11184 |
قاعدة البيانات: | Directory of Open Access Journals |
تدمد: | 09249338 17783585 |
---|---|
DOI: | 10.1192/j.eurpsy.2022.693 |